2 transcripts
EDIT
Earnings call transcript
NASDAQ
2024 Q2
7 Aug 24
will provide a clinical update from the RUBY trial for severe sickle cell disease and the EdiTHAL trial for transfusion-independent beta-thalassemia in mid-2024
EDIT
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
Mani Foroohar with Leerink.
You talked a little bit about improvements in vein-to-vein time as an incremental source of differentiation, independent
- Prev
- 1
- Next